Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: A wait-list - Controlled open trial

Journal of Clinical Psychiatry

Volumn 65, Issue 7, 2004, Pages 922-931

  Tolin, David F ^a,b   Maltby, Nicholas ^a   Diefenbach, Gretchen J ^a   Hannan, Scott E ^a   Worhunsky, Patrick ^a  

^a INSTITUTE OF LIVING   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ADULT; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MENTAL DISEASE; METHODOLOGY; OBSESSIVE COMPULSIVE DISORDER; PATIENT ATTITUDE; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FOLLOW-UP STUDIES; HUMANS; MENTAL DISORDERS; OBSESSIVE-COMPULSIVE DISORDER; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SELECTION; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WAITING LISTS;

EID: 4444289466     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0708     Document Type: Article

References (58)

1. March JS, Frances A, Carpenter D, et al. The Expert Consensus Guideline Series: Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 4):3-72
2. Franklin ME, Foa EB. Cognitive-behavioral treatments for obsessive-compulsive disorder. In: Nathan PE, Gorman JM, eds. A Guide to Treatments That Work. New York, NY: Oxford University Press; 1998
3. Maltby N, Tolin DF. Overview of treatments for obsessive compulsive disorder and spectrum conditions: conceptualization, theory and practice. Brief Treat Crisis Interven 2003;3:127-144
4. Kozak MJ, Foa EB. Mastery of Obsessive-Compulsive Disorder: a Cognitive-Behavioral Approach. San Antonio, Tex: The Psychological Corporation; 1997
5. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997;65:44-52 (Pubitemid 27086134)
6. Cottraux J, Note I, Yao SN, et al. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychother Psychosom 2001;70:288-297 (Pubitemid 34701801)
7. Emmelkamp PM, Beens H. Cognitive therapy with obsessive-compulsive disorder: a comparative evaluation. Behav Res Ther 1991;29:293-300
8. Emmelkamp PM, Visser S, Hoekstra RJ. Cognitive therapy vs exposure in vivo in the treatment of obsessive-compulsives. Cognit Ther Res 1988;12:103-114 (Pubitemid 18095510)
9. van Balkom AJ, de Haan E, van Oppen P, et al. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998;186:492-499 (Pubitemid 28378025)
10. Kozak MJ, Liebowitz MR, Foa EB. Cognitive behavior therapy and pharmacotherapy for obsessive-compulsive disorder: the NIMH-sponsored collaborative study. In: Goodman WK, Rudorfer MV, Maser JD, eds. Obsessive-Compulsive Disorder: Contemporary Issues in Treatment. Mahwah, NJ: Lawrence Erlbaum Associates; 2000:501-530
11. Fals-Stewart W, Marks AP, Schafer J. A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. J Nerv Ment Dis 1993;181:189-193 (Pubitemid 23090175)
12. Foa EB, Steketee G, Grayson JB, et al. Deliberate exposure and blocking of obsessive-compulsive rituals: immediate and long-term effects. Behav Ther 1984;15:450-472 (Pubitemid 15175426)
13. Freeston MH, Ladouceur R, Gagnon F, et al. Cognitive-behavioral treatment of obsessive thoughts: a controlled study. J Consult Clin Psychol 1997;65:405-413 (Pubitemid 27246781)
14. Abramowitz JS, Foa EB, Franklin ME. Exposure and ritual prevention for obsessive-compulsive disorder: effects of intensive versus twice-weekly sessions. J Consult Clin Psychol 2003;71:394-398 (Pubitemid 36323943)
15. Lindsay M, Crino R, Andrews G. Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br J Psychiatry 1997;171:135-139 (Pubitemid 27345145)
16. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 1999;60:584-590 (Pubitemid 29451554)
17. Kampman M, Keijsers GP, Hoogduin CA, et al. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr Scand 2002;106:314-319
18. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. (SCID I/P, version 2.0). New York: Biometrics Research, New York State Psychiatric Institute, 1995
19. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
20. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 2: validity. Arch Gen Psychiatry 1989;46:1012-1016
21. Rauch SL, Jenike MA. Pharmacological treatment of obsessive-compulsive disorder. In: Nathan PE, Gorman JM, eds. A Guide to Treatments That Work. New York, NY: Oxford University Press; 1998:358-376
22. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company; 2000
23. McEvoy GK, ed. AHFS Drug Information, 2000. Bethesda, Md: American Society of Health Systems; 2000
24. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
25. Steer RA, Ball R, Ranieri WF, et al. Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Clin Psychol 1999;55:117-128 (Pubitemid 29044746)
26. Steer RA, Clark DA, Beck AT, et al. Common and specific dimensions of self-reported anxiety and depression: the BDI-II versus the BDI-IA. Behav Res Ther 1999;37:183-190 (Pubitemid 28550449)
27. Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-597 (Pubitemid 26382973)
28. Maier W. The Hamilton Depression Scale and its alternatives: a comparison of their reliability and validity. Psychopharmacol Ser 1990;9:64-71
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
30. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
31. Spielberger CD, Gorsuch RL, Lushene RE, et al. Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting Psychologists Press; 1983
32. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997;27:93-105 (Pubitemid 27407503)
33. Wolpe J. The Practice of Behavior Therapy. 4th ed. New York, NY: Pergamon Press; 1990
34. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behaviors. New York, NY: Guilford Press; 1991
35. Hannan SE, Tolin DF. Obsessive compulsive disorder. In: Orsillo SM, Roemer L, eds. Acceptance and Mindfulness-Based Approaches to Anxiety: Conceptualization and Treatment. New York, NY: Kluwer Academic Publishers. In Press
36. Hayes SC, Strosahl KD, Wilson KG. Acceptance and Commitment Therapy: an Experiential Approach to Behavior Change. New York, NY: Guilford Press; 1999
37. Leung AW, Heimberg RG. Homework compliance, perceptions of control, and outcome of cognitive-behavioral treatment of social phobia. Behav Res Ther 1996;34:423-432 (Pubitemid 26164120)
38. Abramowitz JS, Franklin ME, Zoellner LA, et al. Treatment compliance and outcome in obsessive-compulsive disorder. Behav Modif 2002;26:447-463 (Pubitemid 34851822)
39. Franklin ME, Abramowitz JS, Kozak MJ, et al. Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Consult Clin Psychol 2000;68:594-602 (Pubitemid 30747203)
40. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59:12-19
41. Steketee G, Frost R, Bogart K. The Yale-Brown Obsessive Compulsive Scale: interview versus self-report. Behav Res Ther 1996;34:675-684 (Pubitemid 26316913)
42. Franklin ME, Abramowitz JS, Bux DA, et al. Cognitive-behavioral therapy with and without medication in the treatment of obsessive compulsive disorder. Prof Psychol Res Pr 2002;33:162-168 (Pubitemid 38341622)
43. Maina G, Albert U, Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:33-38 (Pubitemid 32042839)
44. Abramowitz JS, Franklin ME, Street GP, et al. Effects of comorbid depression on response to treatment for obsessive-compulsive disorder. Behav Ther 2000;31:517-528 (Pubitemid 32117708)
45. Fals-Stewart W, Schafer J. MMPI correlates of psychotherapy compliance among obsessive-compulsives. Psychopathology 1993;26:1-5 (Pubitemid 23146383)
46. Steketee G, Chambless DL, Tran GQ. Effects of axis I and II comorbidity on behavior therapy outcome for obsessive-compulsive disorder and agoraphobia. Compr Psychiatry 2001;42:76-86 (Pubitemid 32095068)
47. Foa EB. Failure in treating obsessive-compulsives. Behav Res Ther 1979;17:169-176 (Pubitemid 9206946)
48. Erzegovesi S, Cavallini MC, Cavedini P, et al. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:488-492 (Pubitemid 32937431)
49. Catapano F, Sperandeo R, Perris F, et al. Insight and resistance in patients with obsessive-compulsive disorder. Psychopathology 2001;34:62-68 (Pubitemid 32221249)
50. Maltby N, Tolin DF, Diefenbach GJ. A brief readiness intervention for treatment-ambivalent patients with obsessive-compulsive disorder. Presented to the Association for Advancement of Behavior Therapy; November 14-17, 2002; Reno, Nev
51. Neziroglu F, McKay D, Yaryura-Tobias JA, et al. The Overvalued Ideas Scale: development, reliability and validity in obsessive-compulsive disorder. Behav Res Ther 1999;37:881-902 (Pubitemid 29313441)
52. Eisen JL, Phillips KA, Baer L, et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 1998;155:102-108 (Pubitemid 28037556)
53. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-29 (Pubitemid 26133288)
54. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
55. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002;63:700-703 (Pubitemid 34898434)
56. Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-527 (Pubitemid 29413472)
57. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801 (Pubitemid 30650116)
58. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308 (Pubitemid 24127303)